Cardiovascular Systems completes enrollment in Eclipse clinical trial

Cardiovascular Systems (NASDAQ: CSII)+ this week announced it completed enrollment in its Eclipse coronary trial.

The company enrolled 2,000 patients with severely calcified coronary lesions in the prospective, multicenter, randomized clinical trial. Half of the participants received orbital atherectomy prior to drug-eluting stent implantation, and the other hand received conventional angioplasty, including specialty balloons and DES implantation.

Cardiovascular Systems designed the trial to demonstrate differences in the primary endpoints of post-procedural in-stent minimal cross-sectional area, as well as in the clinical outcome of target vessel failure at one year. The cross-sectional area will be assessed by optical coherence tomography.

Results from the Eclipse study are expected to be shared in the fall of 2024.

“Eclipse is important because it tests two treatment strategies for managing one of the most difficult challenges for interventional cardiologists. We believe the data from this study will be beneficial in defining an optimal treatment plan for patients with severely calcified coronary arteries,” Cardiovascular Systems Chief Medical Officer Jeffrey Chambers said in a news release.

Original Article: (https://www.massdevice.com/cardiovascular-systems-completes-enrollment-in-eclipse-clinical-trial/ )